Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics, Inc. (ANIK)
:ANIK
ANIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.87 - $26.48
Previous CloseN/A
Volume22.29K
Average Volume (3M)138.69K
Market Cap
$134.52M
Enterprise Value$123.79M
Total Cash (Recent Filing)$53.17M
Total Debt (Recent Filing)$24.99M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Oct 30, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding14,418,090
10 Day Avg. Volume121,614
30 Day Avg. Volume138,688
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda-4.25
Forecast
1Y Price Target
$15.50Price Target Upside68.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company's gross margin exceeded forecasts, suggesting efficient cost management.
Financial PerformanceAnika's adjusted EBITDA was better than expected, indicating a stronger than anticipated financial performance.
Bears Say
Clinical TrialsThe Hyalofast trial did not meet its primary endpoints, which contributed to a lower price target for Anika's stock.
Revenue PerformanceAnika generated $26.2 million in revenue, which fell short of the estimated $28.0 million.
Anika Therapeutics News
ANIK FAQ
What was Anika Therapeutics, Inc.’s price range in the past 12 months?
Anika Therapeutics, Inc. lowest stock price was $7.87 and its highest was $26.48 in the past 12 months.
What is Anika Therapeutics, Inc.’s market cap?
Anika Therapeutics, Inc.’s market cap is $134.52M.
When is Anika Therapeutics, Inc.’s upcoming earnings report date?
Anika Therapeutics, Inc.’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.
How were Anika Therapeutics, Inc.’s earnings last quarter?
Anika Therapeutics, Inc. released its earnings results on Jul 30, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.133.
Is Anika Therapeutics, Inc. overvalued?
According to Wall Street analysts Anika Therapeutics, Inc.’s price is currently Undervalued.
Does Anika Therapeutics, Inc. pay dividends?
Anika Therapeutics, Inc. does not currently pay dividends.
What is Anika Therapeutics, Inc.’s EPS estimate?
Anika Therapeutics, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Anika Therapeutics, Inc. have?
Anika Therapeutics, Inc. has 14,418,090 shares outstanding.
What happened to Anika Therapeutics, Inc.’s price movement after its last earnings report?
Anika Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -27.419%.
Which hedge fund is a major shareholder of Anika Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANIK
Anika Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (68.85% Upside)
$15.50 (68.85% Upside)
Blogger Sentiment
Bullish
ANIK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.33%
12-Months-Change
Fundamentals
Return on Equity
-22.91%
Trailing 12-Months
Asset Growth
-28.54%
Trailing 12-Months
Company Description
Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
ANIK Company Deck
ANIK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. There was strong performance from the Integrity product line and progress with Cingal, but notable challenges with Hyalofast's clinical trial results and a decline in overall revenue and gross margin.View all ANIK earnings summariesANIK Stock 12 Month Forecast
Average Price Target
$15.50
▲(68.85% Upside)
Technical Analysis
Ownership Overview
4.25% Insiders
12.82% Mutual Funds
42.68% Other Institutional Investors
29.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---